Radiation Therapy for Thoracic Malignancies.
Sign Up to like & getrecommendations! Published in 2020 at "Hematology/oncology clinics of North America"
DOI: 10.1016/j.hoc.2019.09.007
Abstract: Radiotherapy is the most commonly used nonsurgical modality in treatment of lung cancers, non-small cell lung cancer (NSCLC) in particular. Radiation therapy has been increasingly used as definitive radical treatment, either alone or in combination… read more here.
Keywords: radiation therapy; thoracic malignancies; treatment; radiotherapy ... See more keywords
Antibody drug conjugates in thoracic malignancies.
Sign Up to like & getrecommendations! Published in 2018 at "Lung cancer"
DOI: 10.1016/j.lungcan.2018.07.001
Abstract: Antibody drug conjugates (ADCs) have the potential to alter the efficacy: toxicity ratio of cytotoxic therapy utilizing surface markers on cancer cells as antibody targets to preferentially deliver toxic payloads to tumor cells while limiting… read more here.
Keywords: thoracic malignancies; antibody drug; drug conjugates; lung cancer ... See more keywords
Challenges in Interpretation of Staging PET/CT in Thoracic Malignancies.
Sign Up to like & getrecommendations! Published in 2017 at "Current problems in diagnostic radiology"
DOI: 10.1067/j.cpradiol.2016.11.012
Abstract: 18F-fluorodeoxryglucose (18F-FDG) PET/CT imaging is routinely performed in the evaluation of patients with known or suspected thoracic malignancy. Indications for its use include staging of malignancy, assessment of response to therapy, evaluation of suspected disease… read more here.
Keywords: thoracic malignancies; challenges interpretation; staging pet; pet thoracic ... See more keywords
Racial Diversity and Reporting in United States Food and Drug Administration Registration Trials for Thoracic Malignancies from 2006 to 2020
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Investigation"
DOI: 10.1080/07357907.2022.2131808
Abstract: Abstract There is significant racial disparity in thoracic malignancies in terms of epidemiology and outcomes. We analyzed race reporting and racial diversity in the registration trials of drugs approved by the FDA for thoracic malignancies… read more here.
Keywords: thoracic malignancies; malignancies 2006; registration trials; racial diversity ... See more keywords
Clinical application of comprehensive genomic profiling panel to thoracic malignancies: A single‐center retrospective study
Sign Up to like & getrecommendations! Published in 2022 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.14643
Abstract: The usefulness of comprehensive genomic profiling (CGP) panels for thoracic malignancies after completion of the standard treatment is unclear. read more here.
Keywords: thoracic malignancies; genomic profiling; clinical application; application comprehensive ... See more keywords
Abstract S12-03: Thoracic cancers international COVID-19 collaboration (TERAVOLT): Small-cell lung cancer and other rare thoracic malignancies
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1557-3265.covid-19-s12-03
Abstract: Background: At the last update of the TERAVOLT registry, patients with thoracic malignancies and COVID-19showed a high mortality rate (35 5% overall and 31% due to COVID-19) compared to the general population and toother solid… read more here.
Keywords: thoracic malignancies; rare thoracic; mortality; thoracic ... See more keywords
The efficacy of immune checkpoint inhibitors in thoracic malignancies
Sign Up to like & getrecommendations! Published in 2021 at "European Respiratory Review"
DOI: 10.1183/16000617.0387-2020
Abstract: The advent of immune checkpoint inhibitors (ICIs) has rapidly transformed the treatment paradigm for multiple cancer types, including thoracic malignancies. In advanced non-small cell lung cancer (NSCLC), ICIs have shifted treatment paradigm and improved overall… read more here.
Keywords: cancer; immune checkpoint; small cell; treatment ... See more keywords
Molecular and clinical features of hospital admissions and immunotherapy related adverse events of immune checkpoint inhibitors in thoracic malignancies.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e18192
Abstract: e18192 Background: Immunotherapy related adverse events (irAEs) and hospital admissions with Immune Checkpoint Inhibitors (ICIs) in thoracic malignancies remain poorly characterized. Methods: Admissions after ICIs in all thoracic malignancies patients received ICIs at City of… read more here.
Keywords: immunotherapy related; related adverse; adverse events; hospital admissions ... See more keywords
Platin desensitizations in thoracic malignancies and risk factors for breakthrough reactions.
Sign Up to like & getrecommendations! Published in 2023 at "Allergologia et immunopathologia"
DOI: 10.15586/aei.v51i2.779
Abstract: Although platin desensitization is a safe and effective alternative for patients with hypersensitivity reactions (HSRs), sometimes breakthrough reactions (BTRs) can be encountered. However, data about the risk factors for BTRs are limited. The aim of… read more here.
Keywords: thoracic malignancies; desensitization; breakthrough reactions; risk factors ... See more keywords
Advances in radiation therapy for thoracic malignancies.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of thoracic disease"
DOI: 10.21037/jtd.2018.08.10
Abstract: This special issue of Journal of Thoracic Disease ( JTD ) is a focused review of advances in radiation oncology for thoracic malignancies. The issue covers advances in technology relevant to the practice of radiation… read more here.
Keywords: radiation therapy; advances radiation; thoracic malignancies; oncology ... See more keywords
Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignancies.
Sign Up to like & getrecommendations! Published in 2021 at "Translational lung cancer research"
DOI: 10.21037/tlcr-21-1
Abstract: Background Although most malignancies express cancer-testis antigens (CTA), immune responses to these proteins are limited in thoracic oncology patients. This trial was undertaken to examine if a cancer cell lysate vaccine could induce immunity to… read more here.
Keywords: thoracic malignancies; immune responses; cancer cell; cancer ... See more keywords